Novel Mucosa-homing Dendritic Cell: Development, Trafficking and Function

描述（由申请人提供）：我们的总体目标是定义一种新型肠道归巢树突状细胞（DC）的发展，运输和功能特性。这些粘膜？DC存在于肠固有层和Peyer's补片（PP）以及骨髓（BM）。初步研究提供的见解导致以下一般假设：a) ？DC在表型、微环境定位和发展方面不同于传统的DC亚群。b)它们利用新的运输级联从骨髓的起源回到肠道。c)肠道归巢？DC是肠道DC群体的关键祖细胞，包括CD103+ cDC；它们也可以产生CCR9+浆细胞样DC （pDC）。d) ?独特的TLR反应和效应物活性证明DC可能在粘膜免疫中起特殊作用。因此我们假设？DC既是肠道DC的特化祖细胞，又是肠道免疫应答的参与者。目标包括：目标1。来定义的前体和子代？DC：骨髓发育和肠道DC稳态。？DC和CCR9+ pDC在flt3l刺激的BM培养中产生。为了确定它们的来源，将从BM中分离出常见DC祖细胞（CDP）和其他DC祖细胞，并在体外培养后通过免疫表型检测它们形成DC亚群的情况。排序?还将研究DC，以评估其体外和体内的祖细胞和更新潜力。视黄酸等调节因子对？直流发电将被评估。目标2。来确定的归巢属性？DC与CCR9+ pDC，并定义所涉及的贩运机制。短期归巢分析将决定？DC通过血液迁移到肠道或其他部位，通过流式细胞术监测从受体组织中恢复的细胞的定位。免疫组织化学将用于询问是否？DC会回到肠壁的特定目标微环境。CCR9+ pDC将并行研究以进行比较。来自基因靶向小鼠的中和抗体和/或DC将用于定义涉及的新运输机制/级联。目标3。定义激活（TLR配体）和肠道调节因子（如维甲酸）对？直流。除了他们的祖先活动，？DC刺激T细胞并表现出独特的细胞因子表达模式。？将检测DC对TLR配体的成熟和祖细胞能力的改变；免疫刺激与调节细胞因子的产生；以及对呈递抗原产生反应的T细胞的教育或印记。还将评估肠道相关因子（包括维甲酸和wnt）对其祖细胞与免疫活性的调节作用。阐明肠道相关DC亚群的起源、功能和调控，将有助于我们理解粘膜免疫稳态和对感染的反应；并且有可能导致新的方法来加强粘膜疫苗接种（例如针对HIV或轮状病毒）和控制病理性炎症（例如炎症性肠病或乳糜泻）。

DESCRIPTION (provided by applicant): Our overall goal is to define the development, trafficking, and functional properties of a novel gut-homing dendritic cell (DC). These mucosal "?DC" reside in the intestinal lamina propria and Peyer's patches (PP), and in the bone marrow (BM). Preliminary studies have provided insights leading to the following general hypotheses: a) ?DC are distinct from conventional DC subsets in phenotype, microenvironmental localization, and development. b) They use novel trafficking cascades to home to the gut from their origin in the bone marrow. c) Gut-homing ?DC are key progenitors of intestinal DC populations including CD103+ cDC; and they can also give rise to CCR9+ plasmacytoid DC (pDC). d) ?DC may have specialized roles in mucosal immunity as evidenced by unique TLR responses and effector activities. Thus we hypothesize that ?DC are both specialized progenitors of intestinal DC, and participants in intestinal immune responses. Aims include: Aim 1. To define the precursors and progeny of ?DC: bone marrow development and intestinal DC homeostasis. ?DC, and CCR9+ pDC are generated in Flt3L-stimulated BM cultures. To identify their origin, common DC progenitors (CDP) and other DC progenitors will be sorted from BM, and their development into DC subsets will be monitored by immunophenotyping after in vitro culture. Sorted ?DC will also be studied to evaluate their progenitor and renewal potential in vitro and in vivo. The effects of regulatory factors including retinoic acid on ?DC generation will be assessed. Aim 2. To determine the homing properties of ?DC vs. CCR9+ pDC, and to define trafficking mechanisms involved. Short term homing assays will determine the ability of ?DC to migrate via the blood into the intestines vs. other sites, monitoring localization by flow cytometry of recovered cells from recipient tissues. Immunohistochemistry will be used to ask whether ?DC home to specific target microenvironments in the gut wall. CCR9+ pDC will be studied in parallel for comparison. Neutralizing antibodies, and/or DC from gene-targeted mice, will be used to define novel trafficking mechanisms/cascades involved. Aim 3. To define the effects of activating (TLR ligands) and gut regulatory factors (e.g. retinoic acid) on the progenitor and immunologic activities of ?DC. In addition to their progenitor activities, ?DC stimulate T cells and display unique patterns of cytokine expression. ?DC will be assayed for maturation and altered progenitor ability in response to TLR ligands; production of immunostimulatory vs. modulatory cytokines; and education or imprinting of T cells responding to presented antigen. Regulation of their progenitor vs. immunologic activities by gut-associated factors including retinoic acid and wnts will also be assessed. Elucidating the origin, function and regulation of intestine-associated DC subsets, as proposed here, will help us understand mucosal immune homeostasis and responses to infection; and has the potential to lead to novel approaches to enhance mucosal vaccination (e.g. for HIV or rotavirus) and to control pathologic inflammation (e.g. in inflammatory bowel diseases or celiac disease). PUBLIC HEALTH RELEVANCE: Dendritic cells (DC) are specialized white blood cells that control the body's balance between good (immunity to infection) and bad (for example autoimmune diseases like diabetes or inflammatory bowel disease) immune responses. We have discovered a new kind of mucosa (intestine)- associated DC that acts as a progenitor for other intestinal DC, and that may help control immune responses in the intestines. Our goal is to understand how this mucosal DC develops and gets to the intestines, what controls its differentiation into other DC types, how it responds to infection-related stimuli, and what factors control its contribution to desirable vs. damaging immune responses. In the future our findings may lead to new approaches to enhancing vaccination for AIDS or diarrheal disease, or to treating inflammatory bowel diseases.